相关实验视频
Updated: Jul 2, 2025

05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
162
基于PET的布拉克分期框架在阿尔茨海默氏病中的临床相关性
A C Macedo1, D F P A Durço, C Tissot
1Pedro Rosa-Neto, MD, PhD. The McGill University Research Centre for Studies in Aging, 6875 LaSalle Blvd, Montréal, QC, Canada H4H 1R3, pedro.rosa@mcgill.ca, tel: (+1) 514-761-6131 (ext. 3407).
The journal of prevention of Alzheimer's disease
|February 20, 2024
概括
定子发射断层扫描 (PET) 图像图像与阿尔茨海默病的进展保持一致. 基于PET的布拉克分期与认知衰退和症状严重程度相关,有助于诊断和研究.
科学领域:
- 神经学 神经学
- 放射化学 放射化学是指辐射化学.
- 生物标志物 生物标志物
背景情况:
- 阿尔茨海默病 (AD) 的临床诊断在匹配病理发现方面存在局限性.
- 传统的AD分期依赖于临床评估,而临床评估并不完全符合诸如团之类的组织病理学标志.
- 神经纤维状团的正子发射断层扫描 (PET) 标记器为体内AD分期提供了新的途径.
研究的目的:
- 审查有关AD临床特征与基于PET的 in vivo Braak分期框架之间的关系的文献.
- 评估tau-PET成像对临床AD进展和分期的相关性.
主要方法:
- 叙事文学评论. 叙事文学评论. 叙事文学评论. 叙事文学评论.
- 对与临床AD症状和认知状态相关联的tau-PET成像研究的分析.
- 检查基于PET的布拉克分期框架与疾病严重程度的关系.
主要成果:
- 研究支持随着基于PET的Braak阶段的推进,AD严重程度的逐步增加.
- 后来的布拉克阶段与更糟糕的认知和临床症状相关.
- 图片上的沉积模式与认知状态一致:无损,轻度认知障碍和AD痴呆症.
结论:
- 基于PET的布拉克分期框架与阿尔茨海默病的临床进展有很强的对应性.
- 这种分期系统具有研究和临床实践的潜力,特别是用于识别临床前病理.
- 需要进一步的研究来提高概括性,并充分阐明这个tau-PET分期框架的应用.
相关概念视频
Alzheimer's Disease: Overview
484
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
484
Alzheimer's Disease: Treatment
189
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
189

